Kalytera Therapeutics Inc. (
TSX:V.KALY, KALTF,
Forum) said Tuesday it has retained Colwell Capital to provide investor relations services.
The services to be provided by Colwell will include introducing the company to the Canadian investment community, updating the company’s investor base on a regular basis, organizing investor road shows for the company’s management, and assisting with the preparation of corporate communications and presentations.
More information can be found
here.
Kalytera is a clinical stage pharmaceutical company that is pioneering the use of cannabidiol (“
CBD”) , first for the treatment and prevention of Graft versus Host Disease (GvHD), before expanding into other larger market areas.
Kalytera was in the news recently when it initiated a program to develop a novel Cannabinoid-based compound for treatment of acute and chronic pain.
FULL DISCLOSURE: Kalytera Therapeutics Inc.
is a paid client of Stockhouse Publishing.